Lana Ghanem

We believe clinical research can be built to improve health equity globally. Learning if treatments are safe and effective for the people who need them requires us to offer studies that are more accessible and offer choice. We founded Lightship in 2018 with the inspiration to keep people at the heart of our work and use the latest innovations in digital health, technology, and remote care melded with high quality clinical research to transform clinical trials. Our approach offers clinical trials that are designed from the beginning to make it easier for patients and caregivers to take part. By using inclusive technology, flexible visit types, an amazing experience, and commitment to quality, we can develop programs to better bring new potentially life-saving therapies into the world, together.

Octave® Bioscience Inc. is a commercial stage precision-medicine company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis and expanding into Parkinson’s disease. The Octave Solution includes the Octave MSDA Test, the first and only multivariate blood test for Multiple Sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave is currently collaborating with leading clinics, payers, and pharma companies across the country.

Tact.ai is on a mission to help life science organizations nurture meaningful customer engagement through our human-friendly software. Our AI-powered engagement platform empowers field teams to work with their customers in new ways to drive better outcomes. Tact.ai is headquartered in Silicon Valley and is backed by some of the world’s leading firms in venture capital, technology, and healthcare and life sciences, including Microsoft’s venture fund M12, Salesforce Ventures, Novartis, Lilly and McKesson Ventures. Visit us at: https://www.tact.ai/

At Activ Surgical, our mission is for every surgical imaging system to deliver intelligent information that reduces surgical complication rates, ushering in a new standard of patient care and safety. Having completed the world’s first autonomous robotic surgery of soft tissue in 2018, the company is focused on enhanced, real-time visualization capabilities for surgeons that combine advanced augmented reality (AR), artificial intelligence (AI), and machine learning (ML) technology. Our vision is to transform the collective surgical experience by leveraging emerging technologies and data into insights that make world-class surgery accessible for all.

Launched in the US in 2023, NuvoAir is a purpose-built, integrated specialty care platform that is reinventing the operating model through which care to complex cardiopulmonary patients is delivered. We emphasize the management of exacerbations, the key contributors to high healthcare costs and longitudinal care. Our platform empowers physicians, helping them maintain autonomy, deliver outstanding care and enhance their revenue in ways previously unattainable. By collaborating with health plans, risk-bearing entities, and innovative cardiologists and pulmonologists, we have redefined how patients with complex heart and lung issues, receive high quality care. To discover more about how NuvoAir is advancing high-value care in the cardiopulmonary space and to explore NuvoAirs extensive body of clinical evidence, visit nuvoair.com. Our recruiting email is talent@nuvoair.com, do not hesitate to reach out for any open position. Erin Murphree will be reaching out to you within short notice!

Altoida is a pioneer in developing digital biomarkers of neurological conditions, including Alzheimer’s Disease, using augmented reality and machine learning. Our technology platform is designed to enable an objective evaluation of an individual’s cognitive health and function, which may potentially allow for faster and more sensitive monitoring of disease progression and treatment response. Altoida is a privately-held, venture-backed, commercial stage company and our proprietary evidence-based platform is founded on more than 20 years of scientific research and published in multiple peer-reviewed papers including Nature Digital Medicine.

Like a lighthouse providing early warning in the dark of night, changes in language can signal cognitive decline decades before symptoms of dementia become apparent. Currently, over 47.5 million individuals in the world have dementia, and that number is expected to triple by 2050. At WinterLight Labs, we build technology that can quickly and accurately detect signs of cognitive impairment from a sample of speech. A short 1-5 minute snippet of speech can paint a picture about the speaker's cognitive state, including lexical diversity, syntactic complexity, semantic content, and acoustics. The technology can detect the presence of Alzheimer's Disease with 82% accuracy and aphasia with 100% accuracy. Our software is based on years of experience and academic, peer-reviewed research. Our team continues to actively publish in computer science and neuroscience journals and conferences.

Prognos Health is a real-world data (RWD) company that unlocks the power of data to improve health. Prognos offers the leading managed RWD marketplace, accelerating the development and delivery of innovative therapies and improving health outcomes by offering fully integrated and harmonized lab and health records on more than 325 million de-identified patients. Prognos Healths platform provides a comprehensive and integrated view of patient health, enabling researchers, payers, and providers to make better decisions about care.

Biolinq has created a new Biowearable experience by using an array of electrochemical sensors so small you can barely feel them. Our metabolic health sensors work together to provide maximum reliability for continuous sensing applications. With the potential of multiple analytes such as glucose, ketones, and lactate, we provide an entirely new user experience with actionable metabolic health insights. Over the next 10 years we intend to bring Biosensing and Biowearables mainstream. We are dedicated to the personal and professional growth of all our team members and strive to create a positive and creative work environment.

Our mission is to not only break down the barriers that limit people from getting quality healthcare, but to transform the primary care experience and make personalized healthcare, powered by genetic and non-genetic data, a reality. We’re changing healthcare by offering on-demand telehealth services and building a unique healthcare platform that focuses on prevention and wellness. We foster a collaborative environment where every team member is essential to our mission. By joining the team, your impact will be felt from day one. We’re making a difference in one of the most rapidly-growing industries and we need curious, collaborative and driven people like you to help us change the future of healthcare.

Six in ten Americans live with at least one chronic condition, a leading driver of healthcare costs across the country. Medication non-adherence results in hundreds of billions in wasted costs annually and a higher mortality rate in the U.S. Pillo Health is tackling these issues head-on with an engaging and HIPAA-compliant technology platform dedicated to improving health outcomes for patients at home. Using state of the art technology and artificial intelligence, Pillo Health has developed a voice first care management platform, allowing patients to better manage their health at home, and organizations to deliver digital health solutions directly into the home.

Propeller Health is a precision digital health company on a mission to uplift every person living with chronic disease so they can take control of their health and live a better life. We power motivating, care-connected patient journeys and unify value for all stakeholders – providers, payers, pharma, and other healthcare and life sciences organizations. The Propeller Platform includes FDA-cleared and CE-marked medical devices, consumer apps, support and coaching, and secure access to clinical data for provider monitoring. Our precision approach is designed to motivate behavior change and track patient adherence with the goals of enabling medication optimization and helping predict costly exacerbations. In more than 150 peer-reviewed abstracts and publications, our digital-first chronic respiratory care platform has demonstrated improved quality of life and clinical outcomes while lowering healthcare costs. As a wholly owned subsidiary of ResMed, Propeller brings broad respiratory care expertise, digital therapeutic coverage, and scale globally.

We believe clinical research can be built to improve health equity globally. Learning if treatments are safe and effective for the people who need them requires us to offer studies that are more accessible and offer choice. We founded Lightship in 2018 with the inspiration to keep people at the heart of our work and use the latest innovations in digital health, technology, and remote care melded with high quality clinical research to transform clinical trials. Our approach offers clinical trials that are designed from the beginning to make it easier for patients and caregivers to take part. By using inclusive technology, flexible visit types, an amazing experience, and commitment to quality, we can develop programs to better bring new potentially life-saving therapies into the world, together.

We’re Bank al Etihad, a financial institution that’s proud to be Jordanian. Built on family values, we see every customer as one of our own, and make it our business to help wherever we can.

Octave® Bioscience Inc. is a commercial stage precision-medicine company delivering a new paradigm of care for Multiple Sclerosis and other neurodegenerative diseases. Octave’s Precision Care Solution is the industry’s first set of measurement tools that accurately and objectively measure disease activity, progression, and severity, allowing for better management of complex and high-cost neurodegenerative diseases, starting with Multiple Sclerosis and expanding into Parkinson’s disease. The Octave Solution includes the Octave MSDA Test, the first and only multivariate blood test for Multiple Sclerosis, that measures disease activity, enhanced MRI analytics and protocols, and a clinical care program that tracks and connects patients with MS certified nurse care partners in real time. By combining and analyzing multiple biological and contextual layers of data, delivering longitudinal and holistic perspectives of each patient, and revealing insights at population levels, the Octave Solution addresses unmet needs across the entire ecosystem of care, from patients and providers to pharma and payers. Octave is currently collaborating with leading clinics, payers, and pharma companies across the country.

At Hikma, we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help do this by 1. Living our culture of progress and belonging, being one Hikma, supporting each other, driving onwards, growing Hikma and living by our three values - innovation, caring and collaboration. 2. Delivering on our strategic goals of delivering more from our foundation, building a portfolio that anticipates future health needs and inspiring and enabling our people. 3. Acting responsibly, driving positive impact. We advance health and wellbeing, we empower our people, we protect the environment, and we build trust through quality in everything we do. We are a trusted, reliable partner and dependable source of over 760 high-quality generic, speciality and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 32 manufacturing facilities, 8 R&D centres and c8,80 employees worldwide.

The Arab Palestinian Investment Company (APIC) is a leading investment holding company that was founded by a number of Arab and Palestinian businessmen aiming at steering investments towards Palestine that ultimately contribute to building a viable Palestinian economy. APIC was established and registered in the British Virgins Island as a private shareholding company in 1994. In 1996, it was registered in Palestine as a foreign limited private shareholding company. APIC transformed into a foreign public shareholding company on 23 December 2013 and was listed on the Palestine Exchange on 2 March 2014. The company’s authorized capital is USD 125 million, while its paid-in capital is USD 105 million. APIC aims at providing superior products and services of quality and value leaving a positive and lasting impact in the market. APIC owns a group of subsidiaries operating across manufacturing, retail, distribution and services sectors with presence in Palestine, Jordan, Saudi Arabia, UAE, Iraq & Turkey. Subsidiaries of APIC offer a wide array of products and services through distribution rights agreements with multinational companies that include Philip Morris, Procter & Gamble, Kellogg's, Hyundai, Chrysler, Dodge, Jeep, XL Energy, Abbott, B. Braun, Eli Lilly, GlaxoSmithKline, Sanofi Aventis and Nivea, among many others APIC Subsidiaries: Manufacturing: 1- National Aluminum & Profile Company (NAPCO). 2- Siniora Food Industries Company (Siniora). Retail, Trade & Distribution: 3- Palestine Automobile Company (PAC). 4- Medical Supplies and Services Company (MSS). 5- UNIPAL General Trading Company (Unipal). Services: 6- Sky Advertising, Public Relations and Event Management (Sky). 7- Arab Leasing Company. 8- Arab Palestinian Storage and Cooling Company.